Welcome to our dedicated page for Bausch Health Companies SEC filings (Ticker: BHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bausch Health Companies Inc. filings document regulatory disclosures for a global diversified pharmaceutical company incorporated in British Columbia. The record includes Form 8-K reports for quarterly and annual operating results, Regulation FD updates, clinical-program disclosures, material agreements, debt exchanges and credit-agreement refinancing involving Bausch Health and its subsidiaries, including Bausch + Lomb.
Proxy materials describe annual meeting matters, director elections, auditor approval, executive compensation votes and governance procedures. Other current reports address compensatory arrangements, including performance share unit settlement terms, and capital-structure disclosures tied to senior secured notes, guarantees, collateral arrangements and refinancing transactions.
Bausch Health Companies Inc. reported that Aimee J. Lenar, President, US Pharma, had 5,260 Common Shares withheld on 2026-07-17 at $4.83 per share to satisfy tax withholding obligations upon vesting of Restricted Share Units. After this tax-withholding disposition, she directly holds 371,680 Common Shares.
Aimee J. Lenar, President, US Pharma of Bausch Health Companies Inc., reported a tax-withholding disposition of 23,395 common shares on July 15, 2026 at $4.89 per share. The issuer withheld these shares to satisfy tax obligations on vested Restricted Share Units, leaving her with 376,940 common shares held directly.
Bausch Health Companies Inc. senior vice president, controller and chief accounting officer Steven Hyosig Lee reported a tax-withholding disposition of 3,125 common shares on July 14, 2026, at $4.75 per share, withheld by the issuer to satisfy tax obligations on vesting of Restricted Share Units. Following this, he directly holds 70,114 common shares.
Bausch Health Companies Inc. director Amy B. Wechsler received an equity-based compensation grant rather than cash for her board service for the quarter ending June 30, 2026. She was awarded 1,394 Restricted Share Units, each representing a contingent right to receive one common share.
The grant is recorded at a reference price of $4.93 per share and is classified as a non-derivative acquisition. Following this award, Wechsler’s direct holdings increased to 314,979 common shares, reinforcing that this is a routine compensation-related transaction rather than an open-market purchase.
Paulson John reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director John Paulson reported an equity-based compensation grant and updated his holdings. He received 12,677 Restricted Share Units, issued in lieu of cash compensation for his service on the board for the quarter ending June 30, 2026, each RSU representing one common share at a reference value of $4.93 per share.
Following this grant, Paulson holds 430,242 common shares directly. The filing also reports 73,255,869 common shares held indirectly by investment funds managed by Paulson Capital Inc., where he may be deemed an indirect beneficial owner, while disclaiming beneficial ownership except to the extent of any pecuniary interest.
Bausch Health Companies Inc. director Sandra Leung received an equity compensation grant rather than cash for her board service. She acquired 6,845 common shares on June 30, 2026, valued at $4.93 per share, in the form of Restricted Share Units for the quarter ending June 30, 2026.
Each unit represents a contingent right to receive one common share, and following this grant she directly holds a reported total of 97,070 common shares. This is a routine, compensation-related award rather than an open-market purchase or sale.
Bausch Health Companies Inc. announced that director Michael Goettler has resigned from its Board of Directors, effective June 30, 2026. He is leaving in connection with his appointment as President and Chief Executive Officer of Knoa Pharma LLC.
The company states that Mr. Goettler’s resignation was not due to any disagreement regarding its operations, policies or practices. A press release dated July 1, 2026, describing the resignation is furnished as Exhibit 99.1. Bausch Health describes itself as a global diversified pharmaceutical company with products across multiple therapeutic areas and a controlling interest in Bausch + Lomb Corporation.
WECHSLER AMY B reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director Amy B. Wechsler received an award of 45,871 restricted share units (RSUs) of common shares. The RSUs have a grant date value of $250,000, will vest immediately before the company’s next Annual Meeting of Shareholders, and will be settled in common shares. Following this grant, Wechsler directly holds 313,585 common shares.
ROBERTS EIRY reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director Eiry Roberts received a compensation-related equity grant. On May 22, 2026, she was awarded 45,871 restricted share units (RSUs), which will be settled in common shares at no purchase price. The RSUs have a grant date value of $250,000, vest on the date immediately preceding the company’s next annual meeting of shareholders, and are intended for non-employee directors. Following this grant, Roberts holds 45,871 common shares directly, showing this is an initial or refreshed equity position rather than an open-market purchase or sale.
POWER ROBERT N reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. reported that director Robert N. Power received an equity grant in the form of restricted share units. He was awarded 45,871 RSUs with a grant date value of $250,000, which will vest immediately before the company’s next Annual Meeting of Shareholders and be settled in common shares. Following this grant, he directly holds 300,594 common shares.